The collaboration intends to create novel chemotherapeutic products exhibiting an enhanced safety and efficacy profile by selectively targeting inactive cytotoxic compounds toward tumor cells. The deal makes use
Alferon LDO (Human Leukocyte Derived) is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, and, like Alferon N Injection, should not cause antibody formation, which is
The New Drug Application (NDA) filing for Regnite was backed by the safety and efficacy data from the Phase 2 study in RLS patients. The long-term safety study
The patent, entitled, ‘Compositions and Methods for the Treatment of Premature Ejaculation,’ will provide Israeli patent protection until March 2024, once it is issued. Apricus Bio’s male sexual
As per the collaboaration, Constellation will receive committed funding of $95m, comprising an upfront payment and research funding for a three-year collaboration period. Constellation will also be entitled
Boehringer’s discovery team will apply the drug discovery technology to explore targets that are not easily accessible by other discovery platforms. The XenoGene technology is said to use
Regorafenib is an investigational oral multi-kinase inhibitor targeting angiogenic, stromal and oncogenic kinases and is currently being evaluated in clinical trials for its potential to treat patients with
The data demonstrated that Dimebon did not achieve statistically significant results for either of the two co-primary endpoints including the Alzheimer’s Disease Assessment Scale and the Alzheimer’s Disease
In 2005, Stallergenes used iBOLT to build an online prescription tracking service that streamlined its back-office information flows. Stallergenes has now launched a new project using Magic’s technology,
Natco Pharma chief financial officer P Bhaskara Narayana said that the facility which is worth INR 910m ($17.88m) is ready. "The actual production in the dedicated multiproduction block
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.